Federated Hermes
JNCE

Federated Hermes’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Federated Hermes’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,606
Closed -$6.67K – 2269
2023
Q1 		$6.67K Buy
3,606
+367
+11% +$455 ﹤0.01% 1907
2022
Q4 		$3.6K Buy
3,239
+2,929
+945% +$4.17K ﹤0.01% 1960
2022
Q3 		$1K Buy
+310
New +$1.1K ﹤0.01% 2117
2020
Q4 		– Sell
-64
Closed -$1K – 2373
2020
Q3 		$1K Sell
64
-40,207
-100% -$249K ﹤0.01% 2219
2020
Q2 		$278K Sell
40,271
-9,284
-19% -$50.1K ﹤0.01% 1587
2020
Q1 		$235K Buy
49,555
+46,653
+1,608% +$269K ﹤0.01% 1549
2019
Q4 		$25K Buy
+2,902
New +$15.7K ﹤0.01% 1811
2019
Q3 		– Sell
-362
Closed -$2K – 2314
2019
Q2 		$2K Sell
362
-2,818
-89% -$15K ﹤0.01% 2087
2019
Q1 		$20K Sell
3,180
-4,574
-59% -$22.1K ﹤0.01% 1780
2018
Q4 		$26K Buy
7,754
+5,764
+290% +$26.9K ﹤0.01% 1731
2018
Q3 		$13K Buy
1,990
+1,752
+736% +$13K ﹤0.01% 1914
2018
Q2 		$2K Buy
+238
New +$3.43K ﹤0.01% 2122

Other funds holding JNCE

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Federated Hermes's JNCE Position: Q2 2023 in Review

Federated Hermes sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 3,606 shares — an estimated $6.67K sold.

Federated Hermes first reported a position in JNCE in Q2 2018 and held it in 12 quarters. The position peaked at $278K in Q2 2020. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.

  • Federated Hermes reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Federated Hermes sold 3,606 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $6.67K.
  • Federated Hermes first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2018 and held it in 12 quarters.
  • Federated Hermes's Jounce Therapeutics, Inc. Common Stock position peaked at $278K in Q2 2020.
  • 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Federated Hermes's 13F filing for Q2 2023, filed 14 Aug 2023.